BioGaia has signed four different distribution agreements for the exclusive
rights to sell its oral health products. Agreements have been made with Streuli
Pharma AG for Switzerland, Plac Control for Greece, PharmaPal Drugstore LLC for
United Arab Emirates and George Petrou Ltd for Cyprus.
Further, Sunstar has relaunched the products in Germany.
In all countries the products will be sold under the BioGaia brand and launches
are planned to take place during 2013 and 2014. In September 2013 Sunstar, one
of the world’s leading companies in oral care, relaunched BioGaia’s oral health
products in Germany.
”We are pleased to announce distribution agreements for a further five countries
where BioGaia’s oral health products soon will be available for a large number
of consumers. With the rapidly increasing body of clinical proof for
Lactobacillus reuteri Prodentis and the strong interest in the products among
international distribution partners, we are confident that the oral health area
will become an important part of our business”, says Peter Rothschild, President
BioGaia.
BioGaia’s oral health products contain the patented and well-studied probiotic
Lactobacillus reuteri Prodentis (http://www.biogaia.com/clinical
-studies?field_bg_indication_tid=194&age=All&author=All). The portfolio consists
of lozenges (http://www.biogaia.com/product/biogaia-prodentis-oral-lozenges) and
chewing gum (http://www.biogaia.com/future-launches) for consumers and oil drops
for professional use. Today BioGaia's oral health products are sold in more than
20 countries worldwide.
Latest press releases from BioGaia
2013-10-23 BioGaia AB Interim report 1 January-30 September 2013
2013-10-10 Lactobacillus reuteri Protectis only probiotic effective in treating
colic
2013-08-22 BioGaia AB Interim report 1 January-30 June 2013
BioGaia has published this information in accordance with the Swedish Securities
Market Act. The information was issued for publication on 29 October 2013, 10:30
am CET.
For additional information please contact
Peter Rothschild, Chief Executive Officer, BioGaia: 46 8 555 293 00
BioGaia is a healthcare company that develops, markets and sells probiotic
products with documented health benefits. The products are primarily based on
the lactic acid bacterium Lactobacillus reuteri, which has probiotic, health
-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted
on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com
